NCT05925504 is a Phase 2 clinical trial of Luspatercept in Lower Risk MDS Per IPSS-R, sponsored by Institute of Hematology & Blood Diseases Hospital, China.

Who is sponsoring NCT05925504?

NCT05925504 is sponsored by Institute of Hematology & Blood Diseases Hospital, China.

What drugs are being tested in NCT05925504?

Interventions in NCT05925504: Luspatercept.

What condition does NCT05925504 study?

NCT05925504 studies Lower Risk MDS Per IPSS-R.

Is NCT05925504 still recruiting?

NCT05925504 is currently recruiting now. Last updated 12 March 2024.

Last reviewed 2024-03-12 · How we verify

NCT05925504

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Tapering Dose of Luspatercept in Patients With Lower-risk Myelodysplastic Syndromes

Recruiting now Phase 2 Last updated 12 March 2024

What this trial tests

Phase 2 trial testing Luspatercept in Lower Risk MDS Per IPSS-R in 36 participants. Currently enrolling.

Timeline

1 July 2023

Primary endpoint
30 June 2026

30 September 2026

Quick facts

Lead sponsor	Institute of Hematology & Blood Diseases Hospital, China
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	36
Start date	1 July 2023
Primary completion	30 June 2026
Estimated completion	30 September 2026
Sites	1 location across China

Drugs / interventions tested

Luspatercept (LUSPATERCEPT) — full drug profile →

Conditions studied

Lower Risk MDS Per IPSS-R — all drugs for Lower Risk MDS Per IPSS-R →

Sponsor

Institute of Hematology & Blood Diseases Hospital, China

Who can join

18 and older, any sex, with Lower Risk MDS Per IPSS-R. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective, single center, single-arm, phase 2 study. The aim of this study is to evaluate the efficacy and safety of Luspatercept for Patients with Lower-risk Myelodysplastic Syndromes (MDS).

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting transforming growth factor beta signaling in metastatic osteosarcoma.
Ge R, Huang GM. · · 2023 · cited 25× · PMID 38021074 · DOI 10.1016/j.jbo.2023.100513
Bone marrow microenvironment in myelodysplastic neoplasms: insights into pathogenesis, biomarkers, and therapeutic targets.
Bahmani F, Shayanmanesh M, Safari M, Alaei A, et al · · 2025 · cited 3× · PMID 40349084 · DOI 10.1186/s12935-025-03793-z

Verify or expand the search:

Other trials of Luspatercept

Trials testing the same drug.

NCT07463820 — A Trial Comparing Three Different Treatment Options for Adults With Low-Risk Myelodysplasia and Anemia (A MyeloMATCH Tre · Phase 2 · not yet recruiting
NCT07450313 — The Efficacy and Safety of Luspatercept in Improving Early Anemia After HSCT · Phase 2 · not yet recruiting
NCT07215975 — A Real-World Study to Evaluate Luspatercept in Adults With Transfusion-Dependent Beta-Thalassemia in the Middle East · recruiting
NCT07465029 — A Study of Incidence, Treatment Patterns, and Outcomes in Transfusion-dependent Lower-risk Myelodysplastic Syndromes in · active not recruiting
NCT07362095 — Luspatercept for the Treatment of Anemia Following Allogeneic Hematopoietic Stem Cell Transplantation(Allo-HSCT) · Phase 1, PHASE2 · recruiting

Other Institute of Hematology & Blood Diseases Hospital, China trials

Trials by the same sponsor.

NCT06991920 — Immune-targeted Combination With Chemotherapy for Acute Leukemia of Ambiguous Lineage · NA · not yet recruiting
NCT07407010 — BCMA/CD3 Bispecific Antibody as Bridging Therapy Before CAR-T Cell Infusion in RRMM · Phase 1 · not yet recruiting
NCT07407140 — VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML · Phase 3 · not yet recruiting
NCT07454226 — ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL · NA · not yet recruiting
NCT07490288 — Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05925504 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Institute of Hematology & Blood Diseases Hospital, China
Last refreshed: 12 March 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05925504.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing